Jessica J. Kandel to Antibodies, Monoclonal
This is a "connection" page, showing publications Jessica J. Kandel has written about Antibodies, Monoclonal.
Connection Strength
0.602
-
Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts. J Pediatr Surg. 2002 Mar; 37(3):528-32.
Score: 0.134
-
Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg. 2000 Jun; 35(6):977-81.
Score: 0.119
-
Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg. 2000 Jan; 35(1):30-2; discussion 32-3.
Score: 0.116
-
Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405.
Score: 0.051
-
Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor. J Pediatr Surg. 2003 Nov; 38(11):1569-73.
Score: 0.038
-
Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. Oncol Rep. 2003 Sep-Oct; 10(5):1271-4.
Score: 0.037
-
Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg. 2003 Mar; 38(3):308-14; discussion 308-14.
Score: 0.036
-
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg. 2001 Aug; 36(8):1177-81.
Score: 0.032
-
All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J Pediatr Surg. 2001 Feb; 36(2):287-90.
Score: 0.031
-
Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. J Pediatr Surg. 2002 Mar; 37(3):518-22.
Score: 0.008